269. Pyogenic arthritis Clinical trials / Disease details
Clinical trials : 24 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04901325 (ClinicalTrials.gov) | September 29, 2021 | 17/5/2021 | Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) | Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) | Pyoderma Gangrenosum;Skin Diseases;Wound Heal;Pyoderma;Skin Ulcer | Drug: Baricitinib | Oregon Health and Science University | NULL | Recruiting | 18 Years | 99 Years | All | 20 | Phase 2 | United States |
| 2 | NCT05120726 (ClinicalTrials.gov) | June 2, 2021 | 11/9/2021 | A Novel Therapeutic Treatment of Pyoderma Gangrenosum | A Novel Therapeutic Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Dehydrated human amnion/chorion membrane | Louisiana State University Health Sciences Center in New Orleans | NULL | Recruiting | 18 Years | N/A | All | 20 | Phase 4 | United States |
| 3 | NCT04895566 (ClinicalTrials.gov) | May 24, 2021 | 17/5/2021 | Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma | Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma | Pyoderma;Pyoderma Gangrenosum;Pyoderma Vegetans;Pyoderma Gangrenosum Surrounding Surgical Stoma | Biological: Monoclonal antibody (Mab) sB24M | SWISS BIOPHARMA MED GmbH | NULL | Active, not recruiting | 21 Years | 80 Years | All | 10 | Early Phase 1 | Belarus;Latvia |
| 4 | NCT04274166 (ClinicalTrials.gov) | May 2021 | 12/2/2020 | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: secukinumab 150 mg (2 injections per dose | Wake Forest University Health Sciences | Novartis | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 2 | United States |
| 5 | EUCTR2020-003273-21-PL (EUCTR) | 09/11/2020 | 08/09/2020 | NA | Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). - Exploratory study of IFX-1 in Subjects with Pyoderma Gangrenosum | Pyoderma gangrenosum MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody | InflaRx GmbH | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | United States;Poland | ||
| 6 | NCT03971643 (ClinicalTrials.gov) | May 16, 2019 | 28/5/2019 | Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum | Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima) | Pyoderma Gangrenosum | Drug: IFX-1 | InflaRx GmbH | Innovaderm Research Inc. | Completed | 18 Years | N/A | All | 19 | Phase 2 | United States;Canada;Poland |
| 7 | NCT03311464 (ClinicalTrials.gov) | October 27, 2017 | 12/10/2017 | A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan | A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan | Pyoderma Gangrenosum | Drug: adalimumab | AbbVie | NULL | Completed | 18 Years | N/A | All | 22 | Phase 3 | Japan |
| 8 | NCT03072953 (ClinicalTrials.gov) | June 7, 2017 | 17/2/2017 | Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum | A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: APD334 | Arena Pharmaceuticals | NULL | Terminated | 18 Years | 80 Years | All | 2 | Phase 2 | Australia;New Zealand |
| 9 | NCT03137160 (ClinicalTrials.gov) | May 4, 2017 | 27/4/2017 | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Ixekizumab | Ohio State University | Eli Lilly and Company | Completed | 18 Years | N/A | All | 5 | Phase 2 | United States |
| 10 | NCT02733094 (ClinicalTrials.gov) | April 2016 | 28/3/2016 | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Secukinumab | Technische Universität München | Novartis | Active, not recruiting | 18 Years | 75 Years | All | 8 | Phase 1/Phase 2 | Germany |
| 11 | EUCTR2015-000762-65-DE (EUCTR) | 09/07/2015 | 25/06/2015 | Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu | Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum | Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising. MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Cosentyx® Product Name: Cosentyx Product Code: EU/1/14/980/002; EU/1/14/980/003 | Technische Universität München, School of Medicine, represented by Dean | NULL | Not Recruiting | Female: yes Male: yes | 7 | Phase 2;Phase 3 | Germany | ||
| 12 | NCT02366260 (ClinicalTrials.gov) | February 2015 | 11/2/2015 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Gevokizumab;Drug: Placebo | MedDerm Associates | XOMA (US) LLC | Recruiting | 18 Years | N/A | Both | 5 | Phase 3 | United States |
| 13 | NCT02326740 (ClinicalTrials.gov) | December 2014 | 22/12/2014 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label | XOMA (US) LLC | NULL | Terminated | 18 Years | N/A | Both | 9 | Phase 3 | United States;Australia;Canada |
| 14 | NCT02315417 (ClinicalTrials.gov) | November 2014 | 5/12/2014 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label | XOMA (US) LLC | NULL | Terminated | 18 Years | N/A | Both | 16 | Phase 3 | United States |
| 15 | NCT02318914 (ClinicalTrials.gov) | November 2014 | 8/12/2014 | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab | XOMA (US) LLC | NULL | Terminated | 18 Years | N/A | Both | 15 | Phase 3 | United States;Australia;Canada |
| 16 | NCT01965613 (ClinicalTrials.gov) | January 31, 2014 | 15/10/2013 | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Xilonix | Janssen Research & Development, LLC | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | United States |
| 17 | NCT01882504 (ClinicalTrials.gov) | May 2013 | 17/6/2013 | Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum | An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab | XOMA (US) LLC | NULL | Completed | 18 Years | N/A | Both | 8 | Phase 2 | United States |
| 18 | EUCTR2011-002920-41-DE (EUCTR) | 04/01/2012 | 24/08/2011 | Stelara® (Ustekinumab) treatment in Patients with Pyoderma gangrenosum | Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients. - SPG-Trial | Patients with a clinical diagnosis of Pyoderma gangrenosum MedDRA version: 14.1;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: Stelara Product Name: Ustekinumab Other descriptive name: USTEKINUMAB | University Hospital Tübingen | NULL | Not Recruiting | Female: yes Male: yes | Germany | ||||
| 19 | NCT01302795 (ClinicalTrials.gov) | February 2011 | 17/2/2011 | Canakinumab for Pyoderma Gangrenosum | A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Canakinumab | University of Zurich | NULL | Completed | 18 Years | 99 Years | Both | 5 | Phase 2 | Switzerland |
| 20 | EUCTR2008-008291-14-IE (EUCTR) | 31/03/2010 | 08/10/2009 | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | pyoderma gangrenosum MedDRA version: 9.1;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum MedDRA version: 9.1;Classification code 10037635;Term: Pyoderma gangrenosum | Trade Name: Neoral soft gelatin capsules INN or Proposed INN: CICLOSPORIN Trade Name: Neoral Oral Solution INN or Proposed INN: CICLOSPORIN Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE | Nottingham University Hospitals NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom;Ireland | ||||
| 21 | EUCTR2008-008291-14-GB (EUCTR) | 14/05/2009 | 22/05/2009 | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | pyoderma gangrenosum MedDRA version: 14.0;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders | Trade Name: Neoral soft gelatin capsules INN or Proposed INN: CICLOSPORIN Trade Name: Neoral Oral Solution INN or Proposed INN: CICLOSPORIN Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE | Nottingham University Hospitals NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | Ireland;United Kingdom | ||
| 22 | NCT00730717 (ClinicalTrials.gov) | May 2009 | 4/8/2008 | Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum | Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Humira | Wright State University | Stanford University;Wake Forest University Health Sciences | Withdrawn | 18 Years | N/A | All | 0 | Phase 2 | United States |
| 23 | NCT00791557 (ClinicalTrials.gov) | October 2008 | 13/11/2008 | Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease | An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum | Pyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease | Drug: Infliximab | University Hospitals Cleveland Medical Center | Centocor, Inc. | Completed | 18 Years | 75 Years | All | 2 | N/A | United States |
| 24 | NCT00690846 (ClinicalTrials.gov) | July 2007 | 2/6/2008 | Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum | A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37) | Pyoderma Gangrenosum | Drug: adalimumab | Wake Forest University Health Sciences | NULL | Withdrawn | 18 Years | N/A | All | 0 | Phase 2 | United States |